Insider · CIK 0002069752
Jeffrey Langsam
Files at STLN (Oncology Institute, Inc.). First filing -, latest -.
In brief
Jeffrey Langsam files SEC Form 4 as officer at STLN (Oncology Institute, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Jeffrey Langsam has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 2 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 27, 2026 | STLN Oncology Institute, Inc. | AGrant or award Common Stock | +70,270 | $0.00 | $0 | 127,650 | Apr 1, 2026 |
| May 21, 2025 | STLN Oncology Institute, Inc. | AGrant or award Common Stock | +57,380 | $0.00 | $0 | 57,380 | May 23, 2025 |
Questions about Jeffrey Langsam
Answered from the filings on this page, as of the latest one.
Is Jeffrey Langsam buying or selling?
Jeffrey Langsam has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Jeffrey Langsam's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Jeffrey Langsam has 0.
Where does Jeffrey Langsam file Form 4?
Jeffrey Langsam has filed Form 4 at STLN (Oncology Institute, Inc.) as Chief Clinical Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.